Inclusion Criteria:  ≥1 International Classification of Diseases, Clinical Modification-9/10 (ICD-9/10) code for wet AMD in 2019 ≥1 Healthcare Common Procedure Coding System (HCPCS) code (J code) or National Drug Code (NDC) code for treatment with an anti-VEGF agent (excluding brolucizumab) in 2019 ≥18 years old in 2019 ≥2 wet AMD-related office visits in 2019  Exclusion Criteria:  - ≥1 HCPCS code (J code) or NDC code for treatment with brolucizumab in 2019